Opus Genetics, Inc. (IRD)
| Market Cap | 344.87M +1,049.7% |
| Revenue (ttm) | 11.98M -12.2% |
| Net Income | -106.93M |
| EPS | -1.42 |
| Shares Out | 71.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,283 |
| Open | 4.890 |
| Previous Close | 4.970 |
| Day's Range | 4.730 - 4.937 |
| 52-Week Range | 0.901 - 5.810 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 9.80 (+102.9%) |
| Earnings Date | May 12, 2026 |
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price target is $9.8, which is an increase of 102.90% from the latest price.
News
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics price target lowered to $11 from $12 at Citizens
Citizens lowered the firm’s price target on Opus Genetics (IRD) to $11 from $12 and keeps an Outperform rating on the shares. Recent ARVO data continue to support OPGx-LCA5’s durable…
Opus Genetics reports Q1 EPS (75c), consensus (14c)
Reports Q1 revenue $2.16M, consensus $2.93M. “With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics (IRD) is entering a defining stretch where we believe our…
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepte...
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and I...
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide...
Opus Genetics announces FDA acceptance of OPGx-LCA5 into RDEP program
Opus Genetics (IRD) announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the FDA Rare Disease Evidence Principles, or RDEP, program. OPGx-LCA5 is a potential...
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics price target raised to $10 from $9 at B. Riley
B. Riley raised the firm’s price target on Opus Genetics (IRD) to $10 from $9 and keeps a Buy rating on the shares.
Opus Genetics initiated with an Outperform at Citizens
Citizens initiated coverage of Opus Genetics (IRD) with an Outperform rating and $12 price target The company is developing a portfolio of AAV-based gene therapies for inherited retinal diseases, with...
Opus Genetics management to meet with Piper Sandler
Meeting to be held in New York on April 28 hosted by Piper Sandler.
Opus Genetics to Participate in Leading Medical Conferences in May 2026
RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to...
Opus Genetics management to meet with B. Riley
Meeting to be held in Boston on April 22 hosted by B. Riley.
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therap...
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment - - Strategic financing to accelerate development of earlier-s...
Opus Genetics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Opus Genetics (IRD) with an Overweight rating and $15 price target Clinical data in inherited eye diseases, LCA5 and bestrophinopathies, caused by BEST1 mutatio...
Opus Genetics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Seedhouse initiated coverage of Opus Genetics (IRD) with an Overweight rating and $15 price target
Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therap...
Oppenheimer bullish on Opus Genetics, initiates with an Outperform
As previously reported, Oppenheimer analyst Andreas Argyrides initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target With encouraging initial signals of functional an...
Opus Genetics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target
Opus Genetics files to sell 7.37M shares of common stock for holders
16:57 EDT Opus Genetics (IRD) files to sell 7.37M shares of common stock for holders
Opus Genetics price target raised to $10 from $8 at Wedbush
Wedbush raised the firm’s price target on Opus Genetics (IRD) to $10 from $8 and keeps an Outperform rating on the shares. The firm notes the Q4 update recapped the…
Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year
Reports FY25 revenue $14.196M, consensus $13.48M. “We are delivering a steady cadence of data and milestones across our pipeline,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics (IR...
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA'...
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therap...